API Anti-Tumor Vorinostat Purity Vorinostat Powder Vorinostat

China API Anti-Tumor Vorinostat Purity Vorinostat Powder Vorinostat, Find details about China Vorinostat, Purity Vorinostat from API Anti-Tumor Vorinostat Purity Vorinostat Powder Vorinostat

Basic Info.

Model NO.

Condavo-Vorinostat

Name

Vorinostat

Product Name

Vorinostat Powder

Color

White Color

Test Method

HPLC UV

Storage

Cool Dry Place

Shelf Life

2 Years

Assay

99%

COA

Available

CAS

149647-78-9

C14h20n2o3

264.3202

Density

1.174

Melting Point

161-162c

Refractive Index

1.566

Grade

Medicine Grade

Trademark

Condavo

Transport Package

1kg/ Aluminium Bag or 25kg/Drum; as Required

Specification

99%

Origin

Shaanxi

Model NO.

Condavo-Vorinostat

Name

Vorinostat

Product Name

Vorinostat Powder

Color

White Color

Test Method

HPLC UV

Storage

Cool Dry Place

Shelf Life

2 Years

Assay

99%

COA

Available

CAS

149647-78-9

C14h20n2o3

264.3202

Density

1.174

Melting Point

161-162c

Refractive Index

1.566

Grade

Medicine Grade

Trademark

Condavo

Transport Package

1kg/ Aluminium Bag or 25kg/Drum; as Required

Specification

99%

Origin

Shaanxi

Product Desciption

API Anti-Tumor Vorinostat Purity Vorinostat powder Vorinostat

API Anti-Tumor Vorinostat Purity Vorinostat Powder Vorinostat

Product Name	Vorinostat
CAS	149647-78-9
Appearance	White crystalline powder
MF	C14H20N2O3
MW	264.3202
Purity	99%
Shelf Life	2 Years

Vorinostat is a new type of molecularly targeted anti-tumor drug that inhibits histone deacetylase (HDAC) to cause cell cycle arrest and/or cell death. It is the first HDAC inhibitor approved by the US FDA for the treatment of cutaneous T-cell lymphoma (CTCL) with obvious skin invasion that is still progressing, resistant or recurring after two systemic treatment regimens.

API Anti-Tumor Vorinostat Purity Vorinostat Powder Vorinostat

API Anti-Tumor Vorinostat Purity Vorinostat Powder Vorinostat For the treatment of cutaneous manifestations in patients with cutaneous T-cell lymphoma who have progressive, persistent or recurrent disease on or following two systemic therapies; treatment of CTCL;treating acute myeloid leukemia.
Vorinostat can play a role by inducing cell differentiation, blocking the cell cycle, and inducing cell regulation. Treatment of aggravation, persistence, and recurrence or ineffective cutaneous T-cell lymphoma (CTCL, a non-Hodgkin's lymphoma) after treatment with two systemic drugs. CTCL is a type of T cell carcinoma that affects the white blood cell types of the skin.